---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302098"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2026-07-13T20:46:20+00:00"
generated_at: "2026-07-13T20:47:07.747307+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences appoints Steven Hoerter as CEO, John Smither as CFO; CEO Hawryluk departs

## Summary
- CEO Kent Hawryluk steps down July 13, 2026; will advise through Aug 16, 2026 under consulting agreement.
- Steven Hoerter, former executive Chairman, appointed President and CEO effective July 13, 2026; base salary $665k, target bonus 60%.
- John Smither, interim CFO, appointed CFO effective July 13, 2026; base salary $530k, target bonus 40%, plus $150k relocation bonus.
- New CEO receives 331k stock options and 71k RSUs; new CFO receives 130k options and 28k RSUs, both with 4-year vesting.
- Hawryluk's separation includes 12 months severance, COBRA, target bonus, and accelerated equity vesting through Aug 16, 2027.

## SEC filing metadata
- accession: 0001193125-26-302098
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2026-07-13T20:46:20+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/0001193125-26-302098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/d143977d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302098
- JSON: https://secwatch.observer/filing/0001193125-26-302098.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302098.txt

## Key facts
- Executive change
  Kent P. Hawryluk departed as Chief Executive Officer at MBX Biosciences, Inc..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: Departure of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/0001193125-26-302098-index.htm
- Executive change
  Steven Hoerter was appointed as President and Chief Executive Officer at MBX Biosciences, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On July 9, 2026, the Board appointed Steven Hoerter, the Company’s current executive Chairman of the Board, as President and Chief Executive Officer and principal executive officer of the Company, effective as of July 13, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1776111/000119312526302098/0001193125-26-302098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.